BioSpace News Archive

EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Amarin Corporation plc announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as Interim President and Chief Executive Officer.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection will be featured in 18 presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting from April 23-27.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced the on-line publication of two papers1,2 in the American Journal of Transplantation by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital in collaboration with Tonix Pharmaceuticals.

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce the presentation of a poster at the American Association for Cancer Research annual meeting, in Orlando, Florida, United States, between 14-19 April 2023.

Bright Peak Therapeutics announced the presentation of new data characterizing the highly targeted biological and therapeutic effects of BPT567 that contribute to its potent single agent anti-tumor activity at the American Association for Cancer Research Annual Meeting being held on April 14-19, 2023, in Orlando, FL.

Telix Pharmaceuticals Limited issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March 2023.

NanoViricides, Inc., a clinical stage global leader in nanomedicines against viruses, announced that it has shipped the drug products for impending clinical trials of NV-CoV-2, its COVID drug candidate, to its collaborator, Karveer Meditech Pvt. Ltd., Kolhapur, India.

Gritstone bio, Inc. (Nasdaq: GRTS) today presented 6-month follow up data from its ongoing Phase 1 CORAL-CEPI and CORAL-BOOST studies, which are evaluating the company’s self-amplifying mRNA (samRNA) vaccine candidates against SARS-CoV-2, at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that new preclinical data characterizing the Interleukin 13 (IL-13) Superkines, MDNA132 and MDNA213, and a series of next generation IL-13 Superkine therapies, were presented at the 2023 Annual Meeting of the American Association for Cancer Research (AACR).